Webinar On Transfer of Analytical Methods and Procedures according to USP 1224 Presented By Dr. Ludwig Huber Webinar On Transfer of Analytical Methods.

Slides:



Advertisements
Similar presentations
Why Lab. Certification? Laboratory certification tries to insure that the laboratory is qualified and capable of analyzing the sample and obtaining quality.
Advertisements

PRINCIPLES OF A CALIBRATION MANAGEMENT SYSTEM
The New GMP Annex 11 and Chapter 4 Deadline for coming into operation: 30 June 2011.
Institutional Animal Care and Use Committee (IACUC)
Becoming a MI Bridges Navigation Trainer Michigan Association of United Ways June 21, 2012.
SOP Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Santiago, Chile August.
The New TNI Laboratory Accreditation Standards Requirements for an Accreditation Body.
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
Regulatory Challenges in the Cell Preparation Facility Adrian Gee Center for Cell & Gene Therapy Regulatory Challenges in the Cell Preparation Facility.
Audit of IT Systems SARQA / DKG Scandinavian Conference, October 2002, Copenhagen Sue Gregory.
Cheryl McCarthy Manager, Quality Assurance MBC Session October 3, 2008 GCP Compliance in our Vendors.
Chapter 11 OFFICE MANAGEMENT.
INTERNAL AUDITS OF LABORATORIES Sanjay S Shetgar 1.
Inter-Laboratory Method Transfer
QC/QA Mary Malarkey Director, Division of Case Management Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research March.
Session 6: Data Integrity and Inspection of e-Clinical Computerized Systems May 15, 2011 | Beijing, China Kim Nitahara Principal Consultant and CEO META.
11/2/991 CDER’s 21 CFR Part 11 Implementation Study Greg Brolund Associate Director, Office of Information Technology, CDER/FDA.
Top Tactics for Maximizing GMP Compliance in Blue Mountain RAM Jake Jacanin, Regional Sales Manager September 18, 2013.
Medicaid Hospital Utilization Review and DRG Audits: Frequently Asked Questions The Department of Medical Assistance Services Division of Program Integrity.
FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.
Bodil Mose Pedersen, DHI Status for implementering af ”Quality Manual”
DRAFT Richard Chandler-Mant – R Consultant The Challenges of Validating R Managing R in a Commercial Environment.
© 2006 Jupitermedia Corporation Webcast TitleSuccessful Rollout Planning 1 January 19, :00pm EST, 11:00am PST George Spafford, President Spafford.
World Health Organization
DRAFT Guidance for Industry: Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Drug Listing Denise Sánchez, J.D.,
MethodGXP The Solution for the Confusion.
PCF project cycle Training Workshop : Project Formulation for the Clean Development Mechanism Hanoi, Vietnam September 30 – October 2, 2002.
Top 10 Medical Device Citations
FDA 483 and Warning Letter Interpretation with real Case Studies
1 Importance of Instrument Validation for Accredited Food Export Testing Labs.
PERSONNEL TRAINING IN BIOANALYSIS DR. SHIVPRAKASH MANAGING DIRECTOR SYNCHRON RESEARCH SERVICES PVT. LTD., INDIA.
Good Laboratory Practice CFR 21 Part 58 A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International
Changes without Prior Approval Breakout Session Summary Rick Smith Aventis Pasteur, Inc.
Summary of Assessment Reports and Gap Analysis
Second Annual Japan CDISC Group (JCG) Meeting 28 January 2004 Julie Evans Director, Technical Services.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
United States Department of Agriculture Food Safety and Inspection Service Salmonella Initiative Program Isabel Arrington, PhD, DVM Sci. Advisor, RIMD.
1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.
How to Successfully Apply to the IRB Richard Gordin, IRB Chair True Rubal, Administrator / Director For the Protection of Human Participants in Research.
IWK Research Ethics - Workshop Series Session #2 REB Review Procedures How to submit … October 24, 2013 Bev White, Manager, Research Ethics Research Services,
Overview of FDA's Regulatory Framework for PET Drugs
Welcome New IRB Members! Today we will discuss: Your Role in the IRB: What to Know The IRB Review Process Resources Human Research Protections.
Supervision SICOR Securities, Inc.. Why? NASD 3110 requires the firm to “…establish and maintain a system to supervise the activities of each registered.
APTA Annual Meeting Safety Rulemaking Update October 6, 2015.
Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.
Analysis. Answers. Action. Data Acceptance Workgroup Encouraging acceptance and use of laboratory data by end users Robyn Pyle, MS Specialist,
| |
ISO :2015 Documentation kit for Accreditation of Certifying Body - by Global Manager Group
CM&C Inspections The Pre-Approval Inspection (PAI) in the US 27 May 2010.
EXTERNAL QUALITY CONTROL PROGRAM OF OFFICIAL DRUG QUALITY CONTROL LABORATORIES (EQCP) PROGRAMA DE CONTROL EXTERNO DE CALIDAD DE LABORATORIOS OFICIALES.
Good Laboratory Practice - general information Pirkko Puranen Senior Inspector, Ph.D. Inspectorate.
Responsibilities of Test Facility Management, Study Director, Principal Investigator and Study Personnel G. Jacobs Belgian GLP Monitorate Zagreb, 17 December.
Webinar On 21 CFR Part Quality System Regulation - Applying Principles of Lean Documents and Lean Configuration Presented By Jose Mora Webinar On.
Quarterly Geo/SIG Coordinator Webinar June 25, 2014.
If you can't see this message pleas e us e this linkpleas e us e this link FDAs Expedited Programs for Serious Conditions - Drugs and Biologics Friday,
Analytical Method Validation Under Good Laboratory Practices (GLPs) Webinar Details Date : September 02 nd Friday 2016 Time : 01:00PM ET / 10:00AM PT Duration:
FDA 21 CFR Part 11 Compliance
FDA's Two New Draft Guidance on Software and Device
Simplification of work
FDA's New Enforcement of 21 CFR Part 11
Beverley Alberola, CIP Associate Director, Research Protections
FDA Inspections Stephen Joseph Joy’s Quality Management Systems
The Policies and Processes of the WFME Recognition Program
Lesson 5: BRITE Seminar: GMP II
Overview of ISO 9001:2015 –Quality Management SysteM
Waiving Target Animal Batch Safety Testing for vaccines
Computer System Validation
EXTERNAL QUALITY CONTROL PROGRAM OF OFFICIAL DRUG QUALITY CONTROL
Good Laboratory Practice CFR 21 Part 58
Computer System Validation
Presentation transcript:

Webinar On Transfer of Analytical Methods and Procedures according to USP 1224 Presented By Dr. Ludwig Huber Webinar On Transfer of Analytical Methods and Procedures according to USP 1224 Presented By Dr. Ludwig Huber Contact Us: Hosting By Compliance Trainings Hosting By Compliance Trainings Please visit us at Scheduled On : Wednesday, April 22, 2015 at 13:00 Hrs

Contact Us: We Empower, You Comply! Webinar Description: Transfer of Analytical Methods and Procedures according to USP 1224 When validated methods are transferred between laboratories and sites, their validated state should be maintained to ensure the same reliable results in the receiving laboratory. For a long time there was no official guidance on what exactly is expected to maintain 'the validated state'. Now the USP has published an updated general chapter. Also the FDA has released an official guidance on how to conduct and document method transfer. In addition the FDA has included requirements for method transfer in its new draft guidance from 2014 on validation of analytical methods. This seminar will give a good understanding of USP and FDA requirements and provide recommendations and tools for effective implementation. Product Id FDB1453 Category Food, Drugs & Biologics Scheduled On Wednesday, April 22, 2015 at 13:00 Hrs Duration 75 Minutes Speaker Dr. Ludwig Huber Login at Login at Areas Covered in the Session :  FDA and International expectations for method transfer  Examples of FDA warning letters and how to avoid them  The FDA Guidance on method transfer.  The USP chapter : history, status, future  Four approaches for analytical method transfer and testing  Responsibilities of the transferring and receiving laboratory  Developing a transfer plan and a pre-approval protocol

Who Will Benefit :  Lab Supervisors and Managers  QA managers and personnel  Analysts  Research & Development in Pharmaceutical industry  Pharmaceutical quality control  Contract laboratories  CROs  Consultants  Teachers Price Tags  Conducting comparative studies  Criteria and approaches for risk based testing: what, when, how much?  The importance and selection of acceptance criteria  Dealing with technology transfer: validation requirements, regulatory notification.  Method transfer from standard HPLC to UHPLC  Most likely failures during method transfer  Handling deviations from documented acceptance criteria  Criteria for transfer waiver (omission of formal transfer)  Method transfer protocol and summary report For easy implementation, attendees will receive:  SOP: Transfer of Analytical Methods  Checklist: Transfer of Analytical Methods and Procedures  Master Plan template and examples: - Transfer of Analytical Methods and procedures  Live  Single Live : For One Participant  $ 249  Corporate Live : For Max. 10 Participants  $ 899  Recording  Single REC : For One Participant - Unlimited Access for 6 Months  $ 299

To Register This Webinar Please Visit Contact Us For Immediate or Mail Us At Contact Us For Immediate or Mail Us At Ludwig Huber, Ph.D., is the director of Labcompliance and editor of ( the global online resource for validation and compliance. He is the author of the books "Validation and Qualification in Analytical Laboratories" and "Validation of Computerized Analytical and Networked Systems". He has given multiple presentations mainly on GLP/GMP, 21 CFR Part 11, 21CFR Part 111 and Validation around the world. This included seminars, workshops and presentations for the US FDA, China SFDA, Korea MFDS, Singapore HSA, ISPE, Japan PDA, PIC/S and several other national health care agencies. For more information, please visit Dr.Huber's website ( Speaker Profile